Entering text into the input field will update the search result below

IPSEF Ipsen S.A.
Stock Price & Overview

$109.000.25 (+0.23%)12:10 PM 12/08/23
Pink Limited Info | $USD | Market Close

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Ipsen S.A. logo
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Employees
5,072
Founded
1929
Address
  • 65, quai Georges Gorse
  • Boulogne-Billancourt, 92100
  • France
Phone Number
33 1 58 33 50 00
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.